Reconsidering transcutaneous bilirubinometry for management of neonatal hyperbilirubinemia: is it time for change?

Area of Science:

• Neonatal Medicine
• Pediatric Care
• Clinical Chemistry

Background:

• Current hyperbilirubinemia management relies on total serum bilirubin (TSB), despite concerns about painful neonatal procedures.
• TSB's role as the gold standard for neurotoxicity risk is not directly evidenced.
• TSB measurements have inherent laboratory variability.

Purpose of the Study:

• To evaluate transcutaneous bilirubin assessment (TcB) as a reliable alternative to TSB.
• To explore reducing painful procedures in neonates through TcB utilization.
• To challenge the assumption of TSB's definitive role in assessing neurotoxicity risk.

Main Methods:

• Extensive review of studies correlating transcutaneous bilirubin assessment (TcB) with total serum bilirubin (TSB).
• Analysis of TSB's limitations, including laboratory variability and lack of direct neurotoxicity correlation.
• Evaluation of TcB's advantages: non-invasiveness, reduced turnaround time, and cost-effectiveness.

Main Results:

• TcB's reliability is currently inferred solely from its correlation with TSB.
• TSB levels lack direct evidence linking them to specific risks of bilirubin-induced neurotoxicity.
• TcB avoids invasive procedures, offers faster results, and reduces healthcare costs.

Conclusions:

• TcB can serve as a reliable method for managing neonatal hyperbilirubinemia.
• Standardizing TcB and updating guidelines can significantly decrease painful interventions for neonates.
• Implementing TcB does not appear to elevate the risk of bilirubin neurotoxicity.